Tags

Type your tag names separated by a space and hit enter

The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus.
J Diabetes Complications 2008 Jul-Aug; 22(4):241-5JD

Abstract

OBJECTIVE

The objective of this study was to evaluate the efficacy of venlafaxine HCl in the symptomatic treatment of painful peripheral diabetic neuropathy (PPDN) among patients with type 2 diabetes mellitus (DM).

DESIGN

This study was designed as a prospective, randomized, and controlled trial.

SETTING

This study was conducted at the Dicle University Medical Faculty (Diyarbakir, Turkey).

PATIENTS

Sixty type 2 DM outpatients (47 females and 13 males) with PPDN who had a minimum visual analog scale (VAS) score of 40 mm were enrolled in this study.

INTERVENTIONS

Patients randomized to the treatment group (n=30) received venlafaxine HCl, whereas those randomized to the control group (n=30) received a combination of vitamins B(1)and B(6) tablets.

MEASURES

Severity of pain was measured by VAS, Short-Form McGill Pain Questionnaire, and numerical analog scale scores at admission and at the second, fourth, and eighth weeks of the study. Polyneuropathy was supported by electromyelography.

OUTCOME

In the treatment group, severity of pain was measured as 70.0+/-13.0 in the VAS, as 24.9+/-6.2 in the Short-Form McGill Pain Questionnaire, and as 7.2+/-1.1 in the numerical analog scale. In the control group, it was measured as 73.0+/-8.0 in the VAS, as 26.8+/-6.2 in the Short-Form McGill Pain Questionnaire, and as 7.4+/-0.8 in the numerical analog scale (P>.05).

RESULTS

The most common form of PPDN was distal symmetrical sensorimotor polyneuropathy in both groups (46.8% vs. 50.0%). At the end of the study, there was a significant difference in severity of pain between the groups. In the treatment group, scores were 8.5+/-5.2 and 3.1+/-1.6 in the Short-Form McGill Pain Questionnaire and numerical analog scale, respectively; in the control group, these were 20.5+/-7.0 and 5.5+/-1.6, respectively (P<.001).

CONCLUSIONS

Venlafaxine HCl is a safe and well-tolerable analgesic drug in the symptomatic treatment of PPDN; however, it has minimal adverse effects. It showed its efficacy markedly in the second week of therapy.

Authors+Show Affiliations

Department of Nephrology, Dicle University Medical Faculty, Diyarbakir, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18413214

Citation

Kadiroglu, Ali Kemal, et al. "The Effect of Venlafaxine HCl On Painful Peripheral Diabetic Neuropathy in Patients With Type 2 Diabetes Mellitus." Journal of Diabetes and Its Complications, vol. 22, no. 4, 2008, pp. 241-5.
Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2008;22(4):241-5.
Kadiroglu, A. K., Sit, D., Kayabasi, H., Tuzcu, A. K., Tasdemir, N., & Yilmaz, M. E. (2008). The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 22(4), pp. 241-5. doi:10.1016/j.jdiacomp.2007.03.010.
Kadiroglu AK, et al. The Effect of Venlafaxine HCl On Painful Peripheral Diabetic Neuropathy in Patients With Type 2 Diabetes Mellitus. J Diabetes Complicat. 2008;22(4):241-5. PubMed PMID: 18413214.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. AU - Kadiroglu,Ali Kemal, AU - Sit,Dede, AU - Kayabasi,Hasan, AU - Tuzcu,Alpaslan Kemal, AU - Tasdemir,Nebahat, AU - Yilmaz,M Emin, Y1 - 2008/04/16/ PY - 2006/11/08/received PY - 2007/03/07/revised PY - 2007/03/26/accepted PY - 2008/4/17/pubmed PY - 2008/8/7/medline PY - 2008/4/17/entrez SP - 241 EP - 5 JF - Journal of diabetes and its complications JO - J. Diabetes Complicat. VL - 22 IS - 4 N2 - OBJECTIVE: The objective of this study was to evaluate the efficacy of venlafaxine HCl in the symptomatic treatment of painful peripheral diabetic neuropathy (PPDN) among patients with type 2 diabetes mellitus (DM). DESIGN: This study was designed as a prospective, randomized, and controlled trial. SETTING: This study was conducted at the Dicle University Medical Faculty (Diyarbakir, Turkey). PATIENTS: Sixty type 2 DM outpatients (47 females and 13 males) with PPDN who had a minimum visual analog scale (VAS) score of 40 mm were enrolled in this study. INTERVENTIONS: Patients randomized to the treatment group (n=30) received venlafaxine HCl, whereas those randomized to the control group (n=30) received a combination of vitamins B(1)and B(6) tablets. MEASURES: Severity of pain was measured by VAS, Short-Form McGill Pain Questionnaire, and numerical analog scale scores at admission and at the second, fourth, and eighth weeks of the study. Polyneuropathy was supported by electromyelography. OUTCOME: In the treatment group, severity of pain was measured as 70.0+/-13.0 in the VAS, as 24.9+/-6.2 in the Short-Form McGill Pain Questionnaire, and as 7.2+/-1.1 in the numerical analog scale. In the control group, it was measured as 73.0+/-8.0 in the VAS, as 26.8+/-6.2 in the Short-Form McGill Pain Questionnaire, and as 7.4+/-0.8 in the numerical analog scale (P>.05). RESULTS: The most common form of PPDN was distal symmetrical sensorimotor polyneuropathy in both groups (46.8% vs. 50.0%). At the end of the study, there was a significant difference in severity of pain between the groups. In the treatment group, scores were 8.5+/-5.2 and 3.1+/-1.6 in the Short-Form McGill Pain Questionnaire and numerical analog scale, respectively; in the control group, these were 20.5+/-7.0 and 5.5+/-1.6, respectively (P<.001). CONCLUSIONS: Venlafaxine HCl is a safe and well-tolerable analgesic drug in the symptomatic treatment of PPDN; however, it has minimal adverse effects. It showed its efficacy markedly in the second week of therapy. SN - 1873-460X UR - https://www.unboundmedicine.com/medline/citation/18413214/The_effect_of_venlafaxine_HCl_on_painful_peripheral_diabetic_neuropathy_in_patients_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-8727(07)00038-4 DB - PRIME DP - Unbound Medicine ER -